Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of inebilizumab in IgG4-related disease
CTR20211026Phase 3Active
- Sponsor
- Viela Bio
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inebilizumab in IgG4-related disease (IgG4-RD), sponsored by Viela Bio. Started Oct 2021; status: active.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on CTR20211026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211026.